Hypnosis and VR tested to calm leukemia Patients' fears
NCT ID NCT07386392
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares hypnosis, virtual reality, and standard care to see which best reduces anxiety in adults starting chemotherapy for acute myeloid leukemia. About 99 patients will be randomly assigned to one of three groups. The goal is to find a non-drug way to help patients cope with the stress of diagnosis and intensive treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- hypnosis and virtual reality sessions
- What this could lead to
- If it works, this could offer simple, drug-free ways to ease severe anxiety during leukemia treatment, improving patient well-being.
- What could go wrong
- This is a small pilot study (99 people) that hasn't started yet. The effects may be small or not last, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 99 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient over the age of 18 * Patient diagnosed with acute myeloid leukemia in Western Occitanie * Eligible for first-line induction chemotherapy with anthracycline and cytarabine * Patient able to understand and respond to a self-administered questionnaire * Affiliated with or beneficiary of a social security system * Having signed the research consent form Exclusion Criteria: * Patients diagnosed with acute myeloid leukemia 3 * Patients who were treated in intensive care prior to hospitalization for induction therapy or following induction therapy * Patients with a diagnosed chronic pain-inducing disease (e.g., rheumatoid arthritis), if not stable * Patients with a confirmed diagnosis of psychopathology such as psychosis, depression, or burnout, if not stable * Patients suffering from epilepsy, whether treated or not, or with a history of epilepsy * Patients under guardianship, conservatorship, or legal protection * Pregnant or breastfeeding women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
IUCT Oncopole
Toulouse, France, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a p53-Targeting drug boost chemotherapy in Hard-to-Treat blood cancers?
- Can an HDAC inhibitor wipe out residual leukemia cells?
- Can an experimental pill block a cancer-driving enzyme in hard-to-treat leukemia?
- Two-Drug combo targets leukemia that outsmarted its first treatment
- Tweaking donor cells may shield older transplant patients from a dangerous complication
- Can a drug and donor cells stop leukemia from returning after transplant?